Abstract: Novel sensing technologies for liquid biopsies offer a promising prospect for the early detection of metabolic conditions through -omics techniques. Indeed, high-field NMR facilities are routinely used for metabolomics investigations on a range of biofluids in order to rapidly recognize unusual metabolic patterns in patients suffering from a range of diseases. However, these techniques are restricted by the prohibitively large size and cost of such facilities, suggesting a possible role for smaller, low-field NMR instruments in biofluid analysis. Herein we describe selected biomolecule validation on a low-field benchtop NMR spectrometer (60 MHz), and present an associated protocol for the analysis of biofluids on compact NMR instruments. We successfully detect common markers of diabetic control at low-to-medium concentrations through optimized experiments, including glucose (≤ 2.6 mmol./L) and acetone (25 mol./L), and additionally in readily-accessible biofluids. We present a combined protocol for the analysis of these biofluids with low-field NMR spectrometers for metabolomics, and offer a perspective on the future of this technique appealing to point-of-care applications.
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are recommended for plasma samples. The option is provided for these pulse sequences to be scripted and therefore full automation is possible.
High-field spectra of urine samples were also acquired using a Bruker Avance-I 400 MHz NMR (Leicester School of Pharmacy, De Montfort University, Leicester, UK) spectrometer operating at a frequency of 399.93MHz. The samples were analysed using the noesygppr1d pulse sequence in order to suppress the water signal (δ = ~4.80 ppm) in the urinary samples with irradiation at the water frequency during the recycle and mixing time delays. The free induction decay (FID) was acquired with 32K data points using 128 scans and 2 dummy scans, and 3 µs 1 H pulses, over a sweep width of 4,844 Hz (12.1 ppm) and a receiver gain automatically adjusted to each sample.
60 MHz Spectrometer Biomarker Validation

Calibration
Specific calibration samples of biomolecules relating to diabetes chemopathology were prepared at various concentrations including 1.00-400.00 mmol./L (and 1.00 mol./L), in HPLC-Grade water. For selected metabolites, concentration ranges of 15-800 µM were typically employed. Samples contained 50 µl of 0.05% (w/v) sodium azide, 50 µl of D2O containing 0.05% (w/v) sodium 3-(trimethylsilyl) [2,2,3,3-d4] propionate (TSP), 50 µl of 1.00 M phosphate buffer, and 500 µl of analyte.
This mixture was then rotamixed and added to new 5-mm NMR tubes ready for analysis. 2 H2O containing TSP was used in this case, since sample spectra were acquired on both the 400 and 60 MHz instruments. For the benchtop instrument employed here, 2 H2O is not required as a field-frequency lock solvent. However, as we sought to compare the datasets acquired from both 60 and 400 MHz instruments, 2 H2O was added to facilitate this. TSP is an appropriate internal standard for quantification, (∂ = 0.00 ppm); therefore it does not interfere with other signals. Sodium azide is added to suppress bacterial growth during periods of sample preparation and storage. Phosphate buffer is used to maintain a constant pH value in order to avoid pH-mediated signal shifts: pH 7.00 or 7.40 is recommended [28] . The purpose of the calibration curve is for analytical quantification, and also to determine the limit of detection (LOD); this represents a resonance intensity which is 3 times the background noise value, and the limit of quantification (LOQ), which is derived from a ratio of 10 times this noise level.
60 MHz Benchtop Spectrometer Protocol: Biofluid Analysis Recommendations
[1] Experimental Design and Research Ethics Approval
Prior to sample collection, ethical factors and experimental design should be carefully considered.
All samples in our example study were collected with informed consent and approved by the appropriate Research Ethics Committee, specifically the Faculty of Health and Life Sciences Research Ethics Committee, De Montfort University, Leicester, UK (reference no. 1936). All participants were primarily provided with a participant information sheets (PISs), and were then required to sign a project consent form in the presence of a researcher witness. The PIS clearly informed those recruited that since their participation was voluntary, they had the freedom to withdraw from the investigation at any stage of its progress. Essentially, all ethics considerations were in accord with those of the
Declaration of Helsinki of 1975 (revised in 1983).
A pre-established experimental design is crucial prior to starting sample collection, since factors such as age, sex, BMI, fasting, exercise, stress, drug intake and supplements all affect the metabolome.
Samples can be collected over a period of time to monitor the pharmacokinetics and metabolism of drugs, and samples may be collected randomly, or under pre-fasted or non-fasted conditions. Essentially, the fewer lateral variables available, the more precise the study of the metabolome becomes for that particular disease manifestation. Validation of specific markers includes the performance of larger trials, and/or repetition of the trial by a different laboratory.
Contradictions in metabolomics experiments may commonly arise from experimental error, caused primarily from the high turnover rate of metabolites in terms of stability, solubility and volatility.
Therefore, experimental design is critical for preparation of the experiment itself. Repeat freeze/thaw cycles should be avoided for all sample types [15] , and factors such as maintaining samples at room temperature for a long period of time should be kept to a minimum. Buffering procedures should be kept uniform. It is also important to reduce the number of experimental steps, limit sample handling, process samples rapidly, maintain samples at a cold or frozen state prior to analysis, and analyse as soon as possible thereafter.
[2] Sample Collection and Sample Storage Sample preparation can be automated or manually performed. Automation of samples involves a barcoding system which ensures participant anonymity in such studies. Robotic processing of the samples is also possible, allowing for samples to be prepared and analysed in bulk quantities. This increases productivity, but more importantly displays applicability and viability in a point-of-care setting. It is important to define and follow experimental design and Standard Operational Procedures (SOPs) in order to avoid erroneous results.
Urine
refrain from activities such as smoking, eating, drinking, brushing teeth etc. during the period between waking and sampling, in order to avoid analytical interference from external activities [31, 32] . Saliva samples should be collected in sterile, plastic, universal containers. Specimens should be transported to the laboratory on ice and then centrifuged immediately (3,500 rpm for 15 min.) to remove cells and debris. The supernatants are then stored at -80°C prior to analysis.
Blood Plasma/Serum
Blood should be collected following a 12-hour fasting period. Blood samples are collected by a fully trained phlebotomist via venepuncture. For plasma, lithium heparin tubes should be used for collection to avoid analytical complications arising from the use of tubes containing EDTA or citrate anticoagulants. EDTA or citrate present in collection tubes will not only give rise to interfering resonances themselves, but will also chelate metal ions, i.e. Mg 2+ and Ca 2+ , which themselves generate interfering signals in the 1 H NMR spectra acquired; those of the Ca 2+ -EDTA and Mg 2+ -EDTA complexes, which are distinct from those of EDTA itself in view of a slow exchange of this chelator on the NMR timescale. However, often it is preferable to allow the blood to clot and isolate serum samples therefrom via a simple centrifugation step. Samples should be immediately centrifuged at 4°C, 4,300 rpm for 15 min. Serum and plasma samples are then stored at -80°C prior to analysis.
[3] Sample Preparation Biofluid samples are thawed at ambient temperature and then immediately prepared. Preparation for the test set of samples described herein involved centrifuging 500 µl volumes of sample (plasma, serum, urine or saliva) and removing 450 µl supernatant for analysis. A 50 µl aliquot of phosphate buffer at pH 7.00 (1.00 mol./L) was added to the supernatant, which contained 0.05% (w/v) sodium azide (prepared in HPLC-grade water), and then 50 µl of 2 H2O, also containing 0.05% (w/v) TSP (Sigma-Aldrich, UK), was then added to the solution, so that the final v/v content of this deuterated solvent was 10%. The final added TSP concentration for these mixtures was therefore 264 µmol./L.
Exceptionally for plasma and serum samples, and also other high protein content biofluids such as knee-joint synovial fluid, the TSP singlet resonance is substantially broadened in view of its binding to proteins therein, and hence is best avoided (although it may be included as a standard solution placed in a capillary insert within an NMR tube). Therefore, only 2 H2O was added in this case. This mixture was then rotamixed and transferred to newly-purchased NMR tubes ready for analysis. and 400 MHz spectra. In this format, further preprocessing strategies can be applied to optimise the quality of acquired spectra.
Preferably, signals should be as symmetrical as possible, with a consistent baseline of ~ 0, and have clear, defined and narrow line shapes. Baseline and phase corrections can be manipulated manually for more precise corrections, or automatically using predefined coefficient parameters. Baseline correction allows for manipulation of the spectral baseline, adjusting the entire spectrum to start at a set value of 0. Without baseline corrections, data may show a non-uniform signal area when integrated, which is attributable to fluctuations in the baseline and does not arise from the concentration of particular metabolites present in samples investigated. Phase correction allows for the manipulation of the spectrum to reduce the effect of phase shifting. A poorly adjusted phase correction can result in the absorption signal dipping beneath the spectral baseline, which can lead to the erroneous integration of negative resonance areas. Using a phase correction, the signal region can be manipulated from its negative absorption into the desired pure absorption signal. Apodisation involves multiplying the free induction decay pointwise by a defined function in order to improve the line shape within the spectrum. A Gaussian function is commonly used in view of its ability to improve the resolution of signals by narrowing their linewidths; however this also increases the spectral noise intensity. On occasion, it is prudent to apply a Lorentzian function to improve the signal-to-noise ratio, at a cost of broadening the signals and hence reducing resolution and sine bell functions. The weakness of apodisation occurs when applying a correctional function, causing the resonance to broaden; as such, deformation of signals may occur, potentially leading to the misidentification of multiplets.
[6] Metabolite assignment TSP acts as a reference signal (∂ = 0.00 ppm) for aqueous biofluid analyte samples in order to ensure that metabolites can be chemical shift-aligned accordingly, although alternative or study-specific NMR reference agents, which may also serve as quantitative internal standards, may also be employed. Databases for reference samples include the Human Metabolome Database (HMDB) [13] ,
Madison metabolomics consortium database (MMCD) [33] , and COLMAR metabolomics web server [34] connectivities between nuclei of interest therein. Limitations of databases for authentic biomolecule reference compounds include metabolites predominantly determined at 500-600 MHz operating frequencies, which could lead to problems interpreting spectral data at LF. However, the use of NMR-SIM and Guided Ideographic Spin System Model Optimisation (GISSMO) software strategies enables structural calculations, i.e. simulations of spins at different magnetic fields, and can also afford valuable information on both individual molecules and relatively complex mixtures [35, 36] . Thus, a combination of databases and simulations are the most appropriate approach for structural elucidation strategies using LF instrumentation. [7] Integration and data manipulation Manual bucketing requires the user to observe signals and bucket accordingly; intelligent bucketing is automated and buckets integral datasets according to programming software and the parameters provided, using an algorithm to integrate selected bins. Manual bucketing was performed in the experiments used as examples herein. Since 1 H NMR shifts are critically dependent on temperature, pH and ionic strength, the bucketing step must be carefully performed. Hence, manual integration ensures that only one metabolite signal is incorporated into its corresponding bucket, although there are obviously limitations with may be achieved from this with LF benchtop NMR profiles. Uniform binning was not performed, since this can lead to issues such as signal splitting between and the inclusion of > 1 signal within single buckets.
The buckets were then imported into MS Excel in order to create a 1 H NMR data matrix, and data were normalised by constant sum accordingly. Any buckets attributed to baseline noise, water or other interfering agents were eliminated prior to analysis. Normalisation was also performed by the expression of resonance intensities relative to that of the internal reference (TSP), in order to calculate urinary metabolite concentrations. However, for diabetic urine samples, it was not possible to normalise biomolecule concentrations to those of urinary creatinine at a LF benchtop spectrometer operating frequency of 60 MHz, since the high glucose levels therein significantly overlapped with creatinine's characteristic >N-CH3 and -CH2-function resonances, unlike the 1 H NMR profiles obtained on 400 MHz facilities.
Data filtering was performed in order to primarily remove variables which are unlikely to be of value to the modelling of 1 H NMR datasets.
[8] Reproducibility
To ensure results are reproducible and reliable, within-assay run and between-assay run precisions should be assessed. This is usually performed via the computation of their corresponding components of variance in a pre-designed random effects or mixed model analysis of variance/covariance (ANOVA/ANCOVA) experimental design. Indeed, this ensures that the metabolites being monitored are consistently reported, and avoids any batch-related errors. PCA is an unsupervised technique which helps to detect any statistical 'outliers' in datasets, and following their removal, PC clusterings can be explored for each classification group, if indeed there are any distinguishing metabolic features present. PLS-DA, however, is a supervised technique which is able to seek and evaluate any significant distinctions between datasets using permutation and further testings. PLS-DA is able to distinguish between metabolites causing the most separation between the datasets, and these are statistically validated and cross-validated in order to confirm that the testing performed is sound. Moreover, the CCR technique has the ability to generate reliable metabolomics predictions from datasets in which the number of correlated explanatory metabolite variables (P) is greater or much greater than the sample size (n), irrespective of any multicollinearities between these predictor variables.
Validation of these statistical techniques can be performed using the leave-one-out cross-validation (LOOCV) approach, the Q 2 statistic and area under the receiver operating characteristic (AUROC) curve. AUROC describes the validity of a model based on sensitivity and specificity, i.e. the extent of objects correctly identified within a model, and that of samples correctly classified as 'foreign', respectively. A plot of sensitivity vs. (1-specificity), i.e. true positives vs. false positives, is described as a ROC curve, which extends to a multidimensional hypersurface should there be multiple classes considered. The area under the ROC curve (or AUROC value) acts as a measure of class separation, where a value of unity corresponds to optimal separation between two classes of classification, whilst a value of 0.50 indicates no separation whatsoever [37] .
[10] Computational intelligence (Neural Networks)
Computational intelligence techniques (CITs), including support vector machines (SVMs), optimization algorithms (genetic algorithms, Ants) and machine-learning algorithms (supervised and unsupervised neural networks), can be employed for the analysis of multivariate (MV) 1 H NMR datasets acquired in order to recognize metabolic classification patterns for diseases, as well as disease severity indices for each of several biofluids investigated, i.e. as non-probabilistic binary classifiers. Optimization algorithms can be used to select the most relevant (discriminatory) biomarker variables from the datasets for use in constructing a machine-learning classification model. Random forest (RF) techniques can also be employed for classification and variable selection, in which data is divided into training and test sets. The performance is assessed using an out-of-the-bag (OOB) error value, and the accuracy, specificity and sensitivity can be obtained from the test set. Selforganising maps (SOMs) can explore self-similarities between spectra and hence clusterings that arise from each source of variation involved. The RF model can be repeated multiple times in order to prevent bias arising from the random sub-sampling of the training and test sets. Unsupervised learning methods can also be employed in order to perform data-mining and hence uncover any 'hidden' patterns.
[11] Pathway Identification
The Kyoto Encyclopedia of Gene and Genomics (KEGG), MetaCyc and HMDB each aim to aid in ascribing significant biomolecular modifications identified to imbalances of or perturbations to established metabolic pathways, and can also identify any linkages between cycles. Upregulation and downregulation of cycles can be analysed using these platforms which enable areas of the body/cell/organism to be assessed metabolically. Metaboanalyst also interfaces with these databases.
Moreover, the connectivities of biofluid metabolites that potentially distinguish between diseases and corresponding healthy controls, and also disease severity classification groups, can, in principle, be explored through the Metabolomics software module of Ingenuity Pathways Analysis (IPA, Ingenuity Systems, www.ingenuity.com). Indeed, canonical pathways analysis can be employed to identify those that are the most significantly different between the above disease or severity group classifications.
Case Study: Urinary Profiles of Fasted Diabetic Patients with Elevated Glucose levels
As an example of the above protocol, a case study was performed monitoring glucose levels in type 2 diabetic urine samples, together with additional metabolites which parallel such a marked upregulation in patients with this conditions. Samples were collected and acquired using the above protocols and parameters. The α-glucose anomer C1-H signal at ∂ = 5.23 ppm (d) was detected and integrated, and its intensity expressed relative to that of TSP (s, δ = 0.00 ppm). This particular resonance was employed for quantification purposes since urinary 1 H NMR profiles contain many overlapping signals within the crowded 3.00-4.00 ppm range where its C2-H to C6-H proton resonances are located, and in view of their poor resolution at 60 MHz, this was selected as the optimal resonance to monitor in diabetic and prospectively diabetic patients. Moreover, β-glucose's C1-H resonance (δ = 4.63 ppm) is too closely overlapped with the residual water signal for quantification purposes (Figure 1 ). However, it should be noted that glucose's α-anomer only represents 36% of the total glucose concentration present (the remaining 64% being the β-anomer), and therefore the factor 100/36% (= 2.78) should be employed for converting α-anomer concentrations to total glucose ones. The limit of quantification for glucose was (3.60 mmol/L), and the limit of detection of glucose was (2.88 mmol/L). The calibration curve exhibited a clear linear relationship (r = 0.9911). The limitations of monitoring this α-glucose resonance using LF benchtop NMR analysis is ascribable to potential interference of the closely-located residual water signal. However, we successfully detected and created calibrations for other biomolecules at lower concentrations through optimized experiments, such as acetone, which we found had a LOQ value of ≤ 25 µmol./L using a 60 MHz benchtop facility. metabolomics analysis, notably ketone bodies which arise from the use of lipid sources as a fuel in patients with poorly controlled diabetes. Such a multivariate metabolomics analysis of our LF 60
MHz 1 H NMR dataset was therefore performed, and results arising thereform are outlined below. and Pareto-scaled (Pareto-scaling involves subtraction of the mean bucket value from all bucket observations followed by their division by the square root of that variable's standard deviation, so that each one has a mean value of 0 and a variance not equivalent but similar to unity.
Primarily, 27 univariate two-sample t tests were performed, and when corrected for FDRs, these revealed that there were very highly significant increases in the urinary concentrations of a range of biomolecules in type 2 diabetic patients. Key biomarkers detected using the LF 1 interference from tyrosine's C2/C6 aromatic proton doublet signal; and hippurate as its signal localized within the 7.55-7.71 ppm bucket, the only potential interfering agent being 1-methylhistidine's C4 imidazole ring proton singlet (p = 0.037). Most importantly, glucose, which was determined firstly as a composite bulk carbohydrate ring proton (i.e. C2-H to C6-H) bucket (δ = 3.14-3.99 ppm, p = 2.15 x 10 -6 ), and secondly as the more specific alpha-anomeric proton (i.e. α-C1-H) resonance bucket (δ = 5.17-5.36 ppm, p = 0.038) was also found to be a key biomarker, as expected.
However, as noted above, a complication of the α-C1-H glucose signal is its small fractional overlap with the residual water signal at 60 MHz operating signal. Although the bulk 3.14-3.99 ppm glucose sugar ring proton bucket intensity can be expected to be influenced by those of a range of further urinary metabolite signals also present within this spectral region, we found that when glucose concentrations were > 10 mmol./L, as indeed it was in all 6 of the type 2 diabetic urine samples explored which had detectable glucose levels (it was non-1 H NMR-detectable in 4/10 samples investigated), such interferences were limited in view of the much lower intensities of these further biomolecule signals within this broad spectral region (such as those arising from choline, betaine, trimethylamine N-oxide, taurine, glycine, creatine, glycolate, guanadinoacetate, etc.) than those of the relatively intense α-and β-glucose anomers (i.e. C2-H to C6-H resonances combined).
As an example of multivariate analysis, OPLS-DA was utilized to explore the ability of this strategy to distinguish between the type 2 diabetic and healthy control urinary 1 H NMR profiles acquired. employed as a cut-off for this model, as previously described by Worley and Powers [38] ). Moreover, a permutation test conducted with 2,000 permutations gave p values of < 5 x 10 -4 for both Q 2 and R 2 Y.
Variable importance in projection (VIP) scores and S-plots were utilized in order to identify the most important 1 H NMR bucket variables for discrimination between healthy and type 2 diabetic participants, and those assigned to methylsuccinate (upregulated) and formate (downregulated)
were also found to serve as key biomarker features of this discrimination, in addition to the majority of those detected via the univariate t test analysis described above (including glucose itself, the ketone bodies acetoacetate, acetone and 3-D-hydroxybutyrate, acetate, N-acetyl storage compounds, citrate, creatinine and lactate). The difference between the 1 H NMR metabolic profiles of urine acquired at 60 and 400 MHz operating frequencies for metabolomics analysis is substantial ( Figure 6 ). Indeed, in 1D single-pulse spectra acquired at 60 MHz, the -glucose signal is influenced by the residual water signal at concentrations < 2.8 mmol./L, and increasingly so with decreasing α-glucose level. Moreover, the difference in resolution from 400 MHz to 60 MHz causes significant expansion of multiplet resonances, especially complex second-order ones, at the lower operating frequency. This, in turn, gives rise to resonance overlap problems at 60 MHz, particularly for complex biofluid spectra. Indeed, this resonance δ value expansion would be 400/60 times greater for 60 MHz spectra than it is for 400 MHz ones. For example, the ethanol-CH3 function triplet resonance located at δ = 1.19 ppm, which has a J value of 7.07 Hz, would wholly encompass 2 x 7.07 Hz/60 Hz = 0.235 ppm of the spectral profile at 60 MHz, but only 2 x 7.07 Hz/400 Hz = 0.035 ppm at 400 MHz. The more challenging signals to assign include those from higher-order multiplets and more highly split first-order ones, such as the lactate C-H quartet resonance (δ = 4.13 ppm).
Glucose was clearly 1 H NMR-detectable in 6 out of a total of n = 10 type 2 diabetic urine samples at an operating frequency of 60 MHz, and integration of the 5.26 ppm α-anomeric proton signal followed by its normalisation to internal TSP provided estimates of total urinary glucose levels in our cohort of type 2 diabetic patients. Mean±SEM glucose concentrations were 145±70 mmol./L (range 0-660 mmol./L). Using a mean urinary creatinine (Cn) concentration of 10.09 mmol./L [40] , these mean±SEM values convert to 14.4±6.9 mmol./mmol. Cn. These urinary glucose level values concord with those previously reported in diabetic patients, as noted in Table 1 , although it should be noted that these data correspond to type 1 diabetes or diabetic ketosis. This Table also lists mean glucose concentrations for healthy control subjects, which vary from 9-40 µmol./mol. Cn for adults, 32
µmol./mol. Cn for children, 7-144 µmol./mol. Cn for infants, and 15 µmol./mmol. Cn for new-borns.
A paired sample t test found no significant differences between total glucose concentration determinations performed on a LF benchtop 60 MHz spectrometer and our more conventional HF 400 MHz NMR facility (p = 0.079, n = 10). Moreover, there was an excellent correlation between determinations made on these two analytical systems (r = 9986). [13] .
Disease Age
Group
The significance of urinary glucose levels is not only evident in diabetes patients, but also in patients with conditions such as eosinophilic esophagitis and Fanconi Bickel Syndrome (Table 1) . Therefore, potential applications for using LF-benchtop NMR reach far beyond screening for one disease, a metabolic 'fingerprint' is able to be formed to successfully diagnose multiple diseases. Moreover, monitoring urinary glucose levels is just a single example of what can be achieved using LF NMR analysis. Investigations of other biofluids and corresponding metabolites are possible, and therefore an abundance of metabolic disturbances may be explored with this novel technique.
Discussion
Whilst metabolite analysis in intact biofluids by LF NMR spectroscopy is a newly-advanced technique, it has the potential to impact on 'point-of-care' clinical chemistry diagnosis and monitoring, especially with the increasingly rapid development of spectrometers with operating frequencies > 60 MHz. In comparison, high-field NMR analysis at operating frequencies of 400-800
MHz has become a standard probing tool for the multicomponent analysis of complex biofluids From the protocols and case study described here, a schematic representation has been proposed ( Figure 7 ) in order to allow researchers to follow a protocol for the LF benchtop NMR spectrometroscopc analysis of biolfuids, and which is combined with multivariate metabolomics analysis techniques. This aims to provide full considerations for metabolomics investigations to improve uniformity across the field when using LF benchtop NMR analysis, in order to ensure that some level of protocol uniformity is maintained. expand, and will likely develop further in the field of disease diagnosis and severity monitoring screening.
Conclusions
Future Perspectives
LF benchtop NMR has potential to be used as a point-of-care diagnostic and prognostic screening facility, if suitable protocols and the validation of biomarker analytes as outlined here are adhered to in clinical practices. The technique is advantageous in view of the low running costs and lack of cryogens required when compared to those of higher resolution, HF facilities commonly found in bioanalytical laboratories. Scripting and robotic sampling can ensure full automation of sample preparation and acquisition, which could later be linked to artificial intelligence techniques.
LF benchtop NMR facilities are becoming more sophisticated, enabling multiple solvent suppression regimens on samples which have been extracted in different solvent systems, for example. This would be particularly applicable to extractions using methanol or chloroform from water-based samples subsequent to a lyophilisation procedure. Furthermore, gradients, which are now available on benchtop NMR systems, extend the availability of such techniques for further methodologies to be developed, such as pure shift, which can assist in the confirmation of signal assignments.
Further NMR-active nuclei such as 13 C can also be readily monitored in both simple and complex sample matrices using LF benchtop NMR facilities. However, at present sensitivity for such nuclei is poor, although LOD values for 19 F are reasonably high. Using techniques such as hyperpolarisation could increase the sensitivity of such nuclei, and may be employed adjunctly with this technology.
Internal standard in instrument ERETIC (Electronic Reference To access In Vivo Concentrations) has emerged to remove the addition of internal standard reference agents completely, and reliance on external references such as TSP may become routine in the near future. Issues with internal reference standards may arise from their volatility (as in tetramethylsilane, TMS) and potential to bind to macromolecules in high protein content biofluids such as blood plasma/serum, factors which represent major analytical/bioanalytical disadvantages. The field of applications for these LF NMR techniques is substantial, ranging from food technology through to 'at crime scene site' forensics, and now biomedical imaging in addition to spectroscopy. Whilst miniaturisation of technology has led to improvements in the analytical performance of these facilities, improvements in sensitivity, and the field strength of the permanent rare earth magnets featured in LF benchtop NMR spectrometers, will lead to further advances in the range of applications of these instruments, and their effectiveness therein. 
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